

Erelzi PATIENT ALERT CARD

Etanercept
Solution for Injection

FOLD

Version 1.0 , April 2026

“Important Safety Information”

“It is advised to read carefully before prescribing/
dispensing/administering the product.”

Patient Alert Card

This card contains important safety information you should be aware of before and during treatment with etanercept.

If you do not understand this information, please ask your doctor to explain it to you.

- Show this card to any doctor involved in your treatment.
- Refer to the etanercept package leaflet for more information.
- Keep this card with you for 2 months after your last dose of etanercept, as side effects may occur after your last dose.

Infections

Etanercept may increase your risk of infections, which can be serious.

- You should not use etanercept if you have an infection. If you are unsure, ask your doctor.
- If you develop symptoms suggesting an infection, such as fever, persistent cough, weight loss, or lethargy, seek medical attention immediately.
- You should be assessed for tuberculosis (TB). Ask your doctor to record the dates and results of your latest TB screening below:

Test: _____ Test: _____
Date: _____ Date: _____
Results: _____ Results: _____

Please ask your doctor about your other medications that may increase your risk of infection

FOLD

Additional Information (To be completed)

Patient Name: _____

Doctor's Name: _____

Doctor's Phone Number: _____

It is important that you and your doctor record the brand name and batch number of your medication.

Brand Name: _____

Batch Number: _____

Reporting of side effects:

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in the patient leaflet. You can also report side effects directly via the national reporting system. By reporting side effects, you can help provide more information on the safety of this medicine.

You can report any problem or adverse events or request additional copies of the materials through:

Sandoz Patient Safety Department - Saudi Arabia:
Email: adverse.events.sau@sandoz.com

Saudi Food and Drug Authority National Pharmacovigilance Center
Unified Contact Center: 19999
Email: npc.drug@sfd.gov.sa



يمكنك الإبلاغ عن أي أعراض جانبية أو شكاوى أو لطلب نسخ إضافية من خلال:

شركة ساندوز - السعودية - قسم سلامة المرضى:
الایمیل: adverse.events.sau@sandoz.com

الهيئة العامة للغذاء والدواء، المركز الوطني للتيقظ الدوائي:
مركز الاتصال الموحد: ١٩٩٩٩
الایمیل: npc.drug@sfd.gov.sa

This document has been approved by the Saudi Food and Drug Authority.
هذا الملف تم إعداده من قبل الهيئة العامة للغذاء والدواء في المملكة العربية السعودية.